Ken Griffin Assertio Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.07 - $1.75 $63,558 - $103,950	59,400 Added 29.8%	258,700 $305,000
Q2 2024 Aug 14, 2024	BUY	$0.75 - $1.31 $36,675 - $64,059	48,900 Added 32.51%	199,300 $247,000
Q1 2024 May 15, 2024	SELL	$0.79 - $1.14 $181,682 - $262,174	-229,978 Reduced 60.46%	150,400 $144,000
Q4 2023 Feb 14, 2024	SELL	$1.02 - $2.57 $155,782 - $392,510	-152,728 Reduced 28.65%	380,378 $407,000
Q3 2023 Nov 14, 2023	BUY	$2.52 - $5.69 $215,979 - $487,667	85,706 Added 19.16%	533,106 $1.36 Million
Q2 2023 Aug 14, 2023	BUY	$5.0 - $7.66 $751,500 - $1.15 Million	150,300 Added 50.59%	447,400 $2.42 Million
Q1 2023 May 15, 2023	BUY	$3.54 - $6.66 $535,956 - $1.01 Million	151,400 Added 103.91%	297,100 $1.89 Million
Q4 2022 Feb 14, 2023	SELL	$2.11 - $4.3 $123,224 - $251,120	-58,400 Reduced 28.61%	145,700 $626,000
Q3 2022 Nov 14, 2022	BUY	$2.13 - $4.0 $60,705 - $114,000	28,500 Added 16.23%	204,100 $463,000

31M

957K

38.5K

Ticker ASRT
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 48,178,200
Market Cap $42.4M
Description
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing sp...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.